Shorter anticoagulant treatment should be considered for patients with SLE alone after the first venous thrombotic event, or if SLE is associated with a low risk aPL profile provided that SLE is not in an active phase and that the thrombosis had a well-defined, transitory trigger event. This evidence concerns the gene FASLG and systemic lupus erythematosus.